Ongoing Clinical Trials & Studies

Endo provides required updates around ongoing clinical trials on www.clinicaltrials.gov. To access additional detail about these studies please visit the links provided below.

For inquiries about our ongoing clinical trials, please contact us at clinicaltrials@endo.com.

Expand All

Medical Aesthetics

Study ID

Study Description

Intervention

Study Phase/Type

Recruitment Status* / ClinicalTrials.gov Identifier (if applicable)
EN3835-209 A Phase 2A, Open-Label Study Evaluating the Safety and Different Injection Techniques of CCH for the Treatment of Edematous Fibrosclerotic Panniculopathy (EFP) Collagenase clostridium histolyticum (CCH) Phase 2a Completed
New Window
NCT03632993
EN3835-213 A Phase 2B, Open-Label Study to Explore Tissue Histopathology Following Subcutaneous Injection of Collagenase Clostridium Histolyticum Using An Abdominoplasty Model Collagenase clostridium histolyticum (CCH) Phase 2b Completed
New Window
NCT04236635
EN3835-219 A Phase 2b, Open Label Durability Study of EN3835 Following Treatment of Edematous Fibrosclerotic Panniculopathy No treatment to be administered - Observational only Phase 2b Completed
New Window
NCT03893890
EN3835-220 A Phase 2B, Open-Label Long-Term Durability Study of CCH Following Treatment of Edematous Fibrosclerotic Panniculopathy (Cellulite) No treatment to be administered - Observational only Phase 2b Completed
New Window
NCT04381117
EN3835-224 A Phase 2 Multicenter, Open-Label, Randomized, Parallel-Group, Multiple-Dose Study to Assess the Effectiveness, Safety and Satisfaction With Collagenase Clostridium Histolyticum Grid Technique Injections of Buttock or Thigh Cellulite With Laxity in Adult Females Collagenase clostridium histolyticum (CCH) Phase 2 Active, not recruiting
New Window
NCT04580303
EN3835-304 A Phase 3b, Open-Label, Long-Term Study to Evaluate the Safety and Temporal Pattern of Response of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy (EFP) Collagenase clostridium histolyticum (CCH) Phase 3b Active, not recruiting
New Window
NCT03526549
EN3835-305 A Real World, Multicenter, Open-Label, Multiple Dose Study to Assess the Effectiveness of, and Satisfaction with, CCH Treatment of Buttocks or Thigh Cellulite in Adult Females Collagenase clostridium histolyticum (CCH) Phase 3b Completed
New Window
NCT04170296
EN3835-401 (MOBI-1) Phase 4, Open-Label Study to Assess Effects of Mitigation Treatments on Bruising of CCH-Aaes Treatment of Buttock Cellulite in Adult Females QWO Phase 4 Active, not recruiting
New Window
NCT04677712
Medical Therapeutics

Study ID

Study Description

Intervention

Study Phase/Type

Recruitment Status* / ClinicalTrials.gov Identifier (if applicable)
EN3835-210 A Phase 2, Randomized, Double Blind, Placebo Controlled Study of the Safety and Efficacy of EN3835 for the Treatment of Adhesive Capsulitis of the Shoulder Collagenase clostridium histolyticum EN3835 (CCH) Phase 2 Recruiting
New Window
NCT04496167
EN3835-223 An Observational, Double-blind (Sponsor Open), Long-term Study to Evaluate the Safety and Durability (Efficacy) of Response to EN3835 compared to Placebo in the Treatment of Adhesive Capsulitis of the Shoulder (Frozen Shoulder) No treatment to be administered - Observational only Observational Recruiting
New Window
NCT04680156
Sterile Injectable

Study ID

Study Description

Intervention

Study Phase/Type

Recruitment Status* / ClinicalTrials.gov Identifier (if applicable)
PS4229-101 A Phase 1, Open-Label, Two-Arm, Parallel-Group, Pharmacokinetic Study on Plasma Clearance of Vasopressin in Healthy Volunteers Vasostrict® (vasopressin injection, USP) Phase 1 Completed
New Window
NCT04093050

 newWindow_gray.png By clicking on the link(s) on this page you will leave the Endo.com website and move to an external website(s) independently operated and not managed by Endo Pharmaceuticals. Because Endo Pharmaceuticals does not control the content of the website(s) you are about to visit, and due to its constantly changing nature, we cannot be responsible for its content, accuracy, practices, or standards.

US/RD/CORP/2014/00002a 5/2014